Matrix Protein 2 Vaccination and Protection against Influenza Viruses, Including Subtype H5N1
Figure 5. Results of vaccination and booster with DNA prime–adenovirus (Ad), showing cross-protection. Mice (8–10 per group) were immunized as in Figure 4 or intranasally given a sublethal priming infection with A/PR/8. Three weeks later they were challenged with a high dose of A/PR/8 (1.5x 104 50% lethal dose [LD50]) or moderate dose of A/FM (10 LD50) and monitored for survival. The cumulative survival rate for mice immunized with A/PR/8 and M2-DNA+M2-Ad was significantly higher than that for mice immunized with B/NP-DNA+B/NP-Ad (p<0.001, log rank). Data are representative of multiple experiments.